Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Non-Current Debt (2017 - 2025)

Historic Non-Current Debt for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $20.5 million.

  • Innate Pharma's Non-Current Debt fell 2842.49% to $20.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $20.5 million, marking a year-over-year decrease of 2842.49%. This contributed to the annual value of $24.1 million for FY2024, which is 2796.85% down from last year.
  • As of Q2 2025, Innate Pharma's Non-Current Debt stood at $20.5 million, which was down 2842.49% from $23.8 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Non-Current Debt ranged from a high of $41.0 million in Q4 2022 and a low of $13.4 million during Q2 2022
  • For the 5-year period, Innate Pharma's Non-Current Debt averaged around $25.8 million, with its median value being $23.8 million (2024).
  • Per our database at Business Quant, Innate Pharma's Non-Current Debt crashed by 9989.6% in 2021 and then skyrocketed by 18784.55% in 2023.
  • Quarter analysis of 5 years shows Innate Pharma's Non-Current Debt stood at $15.4 million in 2021, then surged by 165.18% to $41.0 million in 2022, then dropped by 18.69% to $33.3 million in 2023, then decreased by 28.5% to $23.8 million in 2024, then decreased by 13.99% to $20.5 million in 2025.
  • Its last three reported values are $20.5 million in Q2 2025, $23.8 million for Q4 2024, and $28.6 million during Q2 2024.